Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

Ramapriya Ganti, Stephen X. Skapek, Jie Zhang, Christine E. Fuller, Jianrong Wu, Catherine A. Billups, Philip P. Breitfeld, James D. Dalton, William H. Meyer, Joseph D. Khoury

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Both epidermal growth factor receptor (EGFR) and ErbB-2 play an important role in cancer biology and constitute promising molecular targets of therapy. EGFR and ErbB-2 expression has been observed in rhabdomyosarcoma cell lines but not analyzed systematically in rhabdomyosarcoma tumors. Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. Immunostains were assessed for intensity (0: no immunostaining; 1: weak; 2: moderate; 3: strong) and percentage of at least 500 neoplastic cells exhibiting membranous or membranous and cytoplasmic immunostaining. EGFR and ErbB-2 expression was considered positive if the product of intensity and percentage was greater than 10. Patients had a median age of 5.7 years (range 8 months-19.1 years), and of 65/66 patients, 38 were males and 27 were females. Expression of ErbB-2 was identified in 22/66 (33%) cases and tended to be more frequent in the alveolar subtype (13/32, 41%, vs 9/34, 26%, P=0.30). Expression of EGFR was identified in 31/66 (47%) cases and correlated with the embryonal subtype (26/34, 76%, vs 5/32, 16%, P<0.0001) independent of stage, age, and gender. Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma. None of the cases exhibited EGFR or ErbB-2 gene amplification, as assessed using fluorescence in situ hybridization. Furthermore, analysis of 11 additional rhabdomyosarcoma tumors (six alveolar; five embryonal) revealed no evidence of mutations in EGFR exons 18, 19, 20, and 21. In summary, expression of EGFR and/or ErbB-2 is detected in a sizeable subset of rhabdomyosarcoma tumors without evidence of EGFR or ErbB-2 amplification or mutations in the EGFR tyrosine kinase domain. Notably, expression of EGFR correlates with the embryonal subtype, which is also more likely to coexpress EGFR and ErbB-2.

Original languageEnglish (US)
Pages (from-to)1213-1220
Number of pages8
JournalModern Pathology
Volume19
Issue number9
DOIs
StatePublished - Sep 2 2006

Fingerprint

Alveolar Rhabdomyosarcoma
Embryonal Rhabdomyosarcoma
Epidermal Growth Factor Receptor
Rhabdomyosarcoma
Neoplasms
erbB-2 Genes
Mutation
Gene Amplification
Fluorescence In Situ Hybridization

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Ganti, R., Skapek, S. X., Zhang, J., Fuller, C. E., Wu, J., Billups, C. A., ... Khoury, J. D. (2006). Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Modern Pathology, 19(9), 1213-1220. https://doi.org/10.1038/modpathol.3800636

Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. / Ganti, Ramapriya; Skapek, Stephen X.; Zhang, Jie; Fuller, Christine E.; Wu, Jianrong; Billups, Catherine A.; Breitfeld, Philip P.; Dalton, James D.; Meyer, William H.; Khoury, Joseph D.

In: Modern Pathology, Vol. 19, No. 9, 02.09.2006, p. 1213-1220.

Research output: Contribution to journalArticle

Ganti, R, Skapek, SX, Zhang, J, Fuller, CE, Wu, J, Billups, CA, Breitfeld, PP, Dalton, JD, Meyer, WH & Khoury, JD 2006, 'Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma', Modern Pathology, vol. 19, no. 9, pp. 1213-1220. https://doi.org/10.1038/modpathol.3800636
Ganti, Ramapriya ; Skapek, Stephen X. ; Zhang, Jie ; Fuller, Christine E. ; Wu, Jianrong ; Billups, Catherine A. ; Breitfeld, Philip P. ; Dalton, James D. ; Meyer, William H. ; Khoury, Joseph D. / Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. In: Modern Pathology. 2006 ; Vol. 19, No. 9. pp. 1213-1220.
@article{0d9ba726f928486cb211bdd19ae2f670,
title = "Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma",
abstract = "Both epidermal growth factor receptor (EGFR) and ErbB-2 play an important role in cancer biology and constitute promising molecular targets of therapy. EGFR and ErbB-2 expression has been observed in rhabdomyosarcoma cell lines but not analyzed systematically in rhabdomyosarcoma tumors. Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. Immunostains were assessed for intensity (0: no immunostaining; 1: weak; 2: moderate; 3: strong) and percentage of at least 500 neoplastic cells exhibiting membranous or membranous and cytoplasmic immunostaining. EGFR and ErbB-2 expression was considered positive if the product of intensity and percentage was greater than 10. Patients had a median age of 5.7 years (range 8 months-19.1 years), and of 65/66 patients, 38 were males and 27 were females. Expression of ErbB-2 was identified in 22/66 (33{\%}) cases and tended to be more frequent in the alveolar subtype (13/32, 41{\%}, vs 9/34, 26{\%}, P=0.30). Expression of EGFR was identified in 31/66 (47{\%}) cases and correlated with the embryonal subtype (26/34, 76{\%}, vs 5/32, 16{\%}, P<0.0001) independent of stage, age, and gender. Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma. None of the cases exhibited EGFR or ErbB-2 gene amplification, as assessed using fluorescence in situ hybridization. Furthermore, analysis of 11 additional rhabdomyosarcoma tumors (six alveolar; five embryonal) revealed no evidence of mutations in EGFR exons 18, 19, 20, and 21. In summary, expression of EGFR and/or ErbB-2 is detected in a sizeable subset of rhabdomyosarcoma tumors without evidence of EGFR or ErbB-2 amplification or mutations in the EGFR tyrosine kinase domain. Notably, expression of EGFR correlates with the embryonal subtype, which is also more likely to coexpress EGFR and ErbB-2.",
author = "Ramapriya Ganti and Skapek, {Stephen X.} and Jie Zhang and Fuller, {Christine E.} and Jianrong Wu and Billups, {Catherine A.} and Breitfeld, {Philip P.} and Dalton, {James D.} and Meyer, {William H.} and Khoury, {Joseph D.}",
year = "2006",
month = "9",
day = "2",
doi = "10.1038/modpathol.3800636",
language = "English (US)",
volume = "19",
pages = "1213--1220",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma

AU - Ganti, Ramapriya

AU - Skapek, Stephen X.

AU - Zhang, Jie

AU - Fuller, Christine E.

AU - Wu, Jianrong

AU - Billups, Catherine A.

AU - Breitfeld, Philip P.

AU - Dalton, James D.

AU - Meyer, William H.

AU - Khoury, Joseph D.

PY - 2006/9/2

Y1 - 2006/9/2

N2 - Both epidermal growth factor receptor (EGFR) and ErbB-2 play an important role in cancer biology and constitute promising molecular targets of therapy. EGFR and ErbB-2 expression has been observed in rhabdomyosarcoma cell lines but not analyzed systematically in rhabdomyosarcoma tumors. Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. Immunostains were assessed for intensity (0: no immunostaining; 1: weak; 2: moderate; 3: strong) and percentage of at least 500 neoplastic cells exhibiting membranous or membranous and cytoplasmic immunostaining. EGFR and ErbB-2 expression was considered positive if the product of intensity and percentage was greater than 10. Patients had a median age of 5.7 years (range 8 months-19.1 years), and of 65/66 patients, 38 were males and 27 were females. Expression of ErbB-2 was identified in 22/66 (33%) cases and tended to be more frequent in the alveolar subtype (13/32, 41%, vs 9/34, 26%, P=0.30). Expression of EGFR was identified in 31/66 (47%) cases and correlated with the embryonal subtype (26/34, 76%, vs 5/32, 16%, P<0.0001) independent of stage, age, and gender. Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma. None of the cases exhibited EGFR or ErbB-2 gene amplification, as assessed using fluorescence in situ hybridization. Furthermore, analysis of 11 additional rhabdomyosarcoma tumors (six alveolar; five embryonal) revealed no evidence of mutations in EGFR exons 18, 19, 20, and 21. In summary, expression of EGFR and/or ErbB-2 is detected in a sizeable subset of rhabdomyosarcoma tumors without evidence of EGFR or ErbB-2 amplification or mutations in the EGFR tyrosine kinase domain. Notably, expression of EGFR correlates with the embryonal subtype, which is also more likely to coexpress EGFR and ErbB-2.

AB - Both epidermal growth factor receptor (EGFR) and ErbB-2 play an important role in cancer biology and constitute promising molecular targets of therapy. EGFR and ErbB-2 expression has been observed in rhabdomyosarcoma cell lines but not analyzed systematically in rhabdomyosarcoma tumors. Tissue microarray sections representing 66 rhabdomyosarcoma tumors (34 embryonal rhabdomyosarcoma, 32 alveolar rhabdomyosarcoma) were surveyed by immunohistochemistry using antibodies specific for EGFR and ErbB-2. Immunostains were assessed for intensity (0: no immunostaining; 1: weak; 2: moderate; 3: strong) and percentage of at least 500 neoplastic cells exhibiting membranous or membranous and cytoplasmic immunostaining. EGFR and ErbB-2 expression was considered positive if the product of intensity and percentage was greater than 10. Patients had a median age of 5.7 years (range 8 months-19.1 years), and of 65/66 patients, 38 were males and 27 were females. Expression of ErbB-2 was identified in 22/66 (33%) cases and tended to be more frequent in the alveolar subtype (13/32, 41%, vs 9/34, 26%, P=0.30). Expression of EGFR was identified in 31/66 (47%) cases and correlated with the embryonal subtype (26/34, 76%, vs 5/32, 16%, P<0.0001) independent of stage, age, and gender. Coexpression of EGFR and ErbB-2 was identified in eight tumors, of which six were embryonal rhabdomyosarcoma. None of the cases exhibited EGFR or ErbB-2 gene amplification, as assessed using fluorescence in situ hybridization. Furthermore, analysis of 11 additional rhabdomyosarcoma tumors (six alveolar; five embryonal) revealed no evidence of mutations in EGFR exons 18, 19, 20, and 21. In summary, expression of EGFR and/or ErbB-2 is detected in a sizeable subset of rhabdomyosarcoma tumors without evidence of EGFR or ErbB-2 amplification or mutations in the EGFR tyrosine kinase domain. Notably, expression of EGFR correlates with the embryonal subtype, which is also more likely to coexpress EGFR and ErbB-2.

UR - http://www.scopus.com/inward/record.url?scp=33747598681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747598681&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800636

DO - 10.1038/modpathol.3800636

M3 - Article

VL - 19

SP - 1213

EP - 1220

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 9

ER -